United Kingdom Cell and Gene Therapy Cold Chain Logistics Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2025)

USD 105.6 Million

Market (2034)

USD 430.52 Million

CAGR

16.90%

Major Markets Players

Atelerix Ltd., Life Science Group Ltd (LSG), Arvato Group, DGP Intelius Ltd., QuickSTAT (A Kuehne + Nagel Company) and Others

*Note: Partial List Randomly Ordered

United Kingdom Cell and Gene Therapy Cold Chain Logistics Market Statistics and Insights

United Kingdom Cell and Gene Therapy Cold Chain Logistics Market Insights & Analysis

The United Kingdom Cell and Gene Therapy Cold Chain Logistics Market is anticipated to register a 16.90% during 2026–2034. The market size was valued at USD 105.6 million in 2025 and is projected to reach USD 430.52 million by 2034. The United Kingdom is one of Europe’s leading hubs for cell and gene therapy research, clinical development, and commercialization. Strong academic research, advanced healthcare infrastructure, and supportive regulatory pathways have accelerated the development of advanced therapies, directly increasing demand for specialized cold chain logistics.

Cell and gene therapies require stringent temperature control, real-time monitoring, and secure chain-of-custody management. The increasing number of clinical trials, personalized therapies, and cross-border shipments has significantly expanded demand for cryogenic and ultra-low temperature logistics solutions. Strategic collaborations between biopharmaceutical companies, logistics providers, and technology firms are strengthening the UK’s advanced therapy supply chain ecosystem.

United Kingdom Cell and Gene Therapy Cold Chain Logistics Market Dynamics

Key Market Driver: Rapid expansion of advanced therapy pipelines

The United Kingdom Cell and Gene Therapy Cold Chain Logistics Market is primarily driven by the rapid expansion of cell and gene therapy pipelines. The UK’s strong presence in regenerative medicine, supported by government-backed innovation programs and expedited approval pathways, has accelerated therapy development and commercialization. Increasing adoption of autologous and allogeneic therapies requires precise temperature-controlled logistics, particularly cryogenic transport. Growing investments from pharmaceutical and biotechnology companies further intensify demand for specialized cold chain services across the country.

Major Industry Challenge: Operational complexity and compliance requirements

High operational complexity poses a significant challenge for the United Kingdom Cell and Gene Therapy Cold Chain Logistics Market. Maintaining ultra-low temperatures throughout storage and transportation requires advanced infrastructure, trained personnel, and continuous monitoring. Strict regulatory compliance related to data integrity, patient safety, and product traceability adds further complexity. Any temperature deviation can lead to product loss, making risk mitigation and quality assurance critical priorities for logistics providers.

Emerging Trend Shaping Outlook: Integration of digital cold chain management platforms

An emerging trend in the United Kingdom Cell and Gene Therapy Cold Chain Logistics Market is the integration of digital cold chain management platforms. Advanced tracking systems, real-time temperature sensors, and chain-of-identity solutions are increasingly adopted to enhance visibility and compliance. Logistics providers are offering integrated, end-to-end solutions covering packaging, storage, transport, and last-mile delivery. This trend is improving reliability, reducing operational risks, and supporting the scalability of advanced therapy supply chains.

United Kingdom Cell and Gene Therapy Cold Chain Logistics Market Segment-wise Analysis

Segment-wise evaluation highlights how logistics infrastructure components, service offerings, and transportation modes influence market demand and revenue contribution across the United Kingdom.

By Component

• Cryogenic Shippers
• Cryogenic Storage Freezers
• Ultra-Low Freezers
• Cold Chain Management Systems
• Shipment and Storage Medium
• Cryogenic Packout Kits
• Others

Cryogenic shippers dominate with approximately 38% market share due to their critical role in transporting temperature-sensitive cell and gene therapies. Cryogenic storage freezers account for nearly 22%, supported by increasing demand for long-term storage. Ultra-low freezers contribute around 17%, while cold chain management systems and supporting components collectively account for the remaining share.

By Services Offered

• Transportation
• Storage
• Packaging

Transportation services lead with approximately 44% market share, driven by frequent domestic and international shipments. Storage services account for nearly 31%, supported by growing clinical trial inventories. Packaging services contribute around 25%, driven by demand for validated and compliant cryogenic packaging solutions.

By Mode of Transportation

• Air
• Ground
• Water

Air transport dominates with approximately 52% market share due to time-sensitive and international shipments. Ground transportation accounts for nearly 38%, driven by domestic distribution between research centers, hospitals, and manufacturing sites. Water transport contributes a limited share, primarily for non-urgent bulk logistics.

Regional Projection of United Kingdom Cell and Gene Therapy Cold Chain Logistics Market

Regional demand reflects concentration of biopharmaceutical activity, research institutions, and healthcare infrastructure across the United Kingdom.

• London
• South East England
• North West England
• Midlands
• Rest of United Kingdom

London accounts for over 34% market share due to a high concentration of biotech firms, hospitals, and research institutions. South East England follows with strong manufacturing and logistics infrastructure. North West England and the Midlands show growing demand supported by life sciences clusters. Other regions contribute steady growth through expanding clinical and healthcare networks.

United Kingdom Cell and Gene Therapy Cold Chain Logistics Market Future Outlook (2034)

The United Kingdom Cell and Gene Therapy Cold Chain Logistics Market is expected to reach USD 430.52 million by 2034, expanding at a CAGR of 16.90%. Growth will be driven by increasing commercialization of advanced therapies, rising clinical trial activity, and growing demand for personalized medicine. Cryogenic logistics, digital monitoring, and integrated service models will continue to gain prominence. Logistics providers investing in automation, data-driven platforms, and regulatory-compliant infrastructure will be well positioned for long-term growth. The UK’s leadership in cell and gene therapy innovation will remain a strong foundation for sustained market expansion.

Why Choose This Report?

• Provides comprehensive insights into United Kingdom Cell and Gene Therapy Cold Chain Logistics Market dynamics
• Offers accurate market size, segmentation, and growth forecasts
• Supports strategic planning with competitive benchmarking
• Enhances understanding of advanced therapy supply chain requirements
• Consolidates market intelligence for efficient research
• Identifies emerging opportunities and operational challenges
• Supports investment and expansion strategies
• Based on real market behavior and regional analysis